搜尋

file (3)

What We Do

學術發表

首頁學術發表

2020.Nov.19

Vaccine

OBI-833 was safe and immunogenic, without treatment-related SAEs, in a phase I dose-escalation trial

Presentation Slides

2020.Jul.22

Vaccine

Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study

2020.May.29

Prodrug

A First-In-Man Phase 1/2 Study of OBI-3424, an AKR1C3-Selective Bis-Alkylating Agent Prodrug, in Subjects With Advanced Cancer, Including Hepatocellular Carcinoma (HCC) and Castrate-Resistant Prostate Cancer (CRPC)

Poster

2020.May.29

Vaccine

The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High Risk, Early-Stage, Globo H-Positive, Triple Negative Breast Cancer

Poster

2020.May.29

ADC

A Phase 1/2, Open‑Label, Dose-Escalation, and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI‑999 in Patients with Advanced Solid Tumors.

Poster

2019.Jul.21

ADC

Novel Globo H-targeting antibody-drug conjugate with binding specificity and anti-tumor efficacy in multiple cancer types

Poster

2019.Jul.15

Prodrug

OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

2019.Jul.01

Vaccine

Specificity, biodistribution, tumor targeting, and pharmacokinetics of a novel humanized anti-Globo H antibody, OBI-888, for cancer immunotherapy

Poster

2019.Jul.01

Vaccine

Anti-tumor efficacy and potential mechanism of action of a novel therapeutic humanized anti-Globo H antibody, OBI-888

Poster

2019.Feb.11

Others

Signaling pathway of globo-series glycosphingolipids and β1,3-galactosyltransferase V (β3GalT5) in breast cancer